March 7th 2025
The FDA has accepted the resubmission of a BLA for odronextamab for the treatment of patients with relapsed/refractory follicular lymphoma.
Adding Pembrolizumab to COPDAC-28 Consolidation May Augment Responses in Classical Hodgkin Lymphoma
September 4th 2023Patients with high-risk classical Hodgkin lymphoma who experience a slow early response to frontline chemotherapy may benefit from the addition of pembrolizumab to COPDAC-28 consolidation.
Liso-cel Demonstrates Rapid, Durable Responses in Patients with Relapsed/Refractory CLL/SLL
June 24th 2023The phase 1/2 TRANSCEND CLL 004 trial met its primary end point by demonstrating that lisocabtagene maraleucel elicited responses in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
Nivolumab Plus AVD Confers PFS Benefit for Treatment of Advanced-Stage Hodgkin Lymphoma
June 4th 2023Patients with advanced-stage Hodgkin lymphoma who received nivolumab plus AVD experienced a 1-year estimated progression-free survival rate of 94% meeting the primary end point of the phase 3 SWOG S1826 trial.
Epcoritamab Obtains Accelerated Approval for Relapsed/Refractory DLBCL
May 19th 2023The FDA has granted epcoritamab accelerated approval for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. The prescribing label comes with boxed warnings for cytokine release syndrome and neurologic problems.
ODAC Votes in Favor Of Polatuzumab Vedotin in Patients With Treatment Naïve LBCL
March 10th 2023The FDA’s Oncologic Drugs Advisory Committee voted 11 to 2 in support of the benefit-risk profile displayed by polatuzumab vedotin-piiq in patients with previously untreated large B-cell lymphoma, including diffuse large B-cell lymphoma not otherwise specified.
Smith Discusses Importance of Adherence When Integrating Pirtobrutinib Into Clinical Practice
March 7th 2023Leslie Smith, DNP, RN, APRN-CNS, BMTCN, AOCNS, highlights the pirtobrutinib approval for mantle cell lymphoma, and what she anticipates will encompass best nursing practices with the newly approved agent.
Magrolimab Plus Rituximab/Chemo Delivers Responses in Relapsed/Refractory DLBCL
February 3rd 2023At 11.3 months of follow-up, magrolimab, rituximab, gemcitabine, and oxaliplatin yielded an overall response rate of 51.5%, including a complete response rate of 39.4%, among patients with relapsed or refractory diffuse large B-cell lymphoma.
FDA Approves Zanubrutinib for CLL/SLL
January 19th 2023The FDA has approved zanubrutinib for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. The prescribing label comes with warnings for hemorrhage, infections, cytopenias, second primary malignancies, and cardiac arrythmias.
Zanubrutinib Outperforms Ibrutinib in Head-to-Head Trial for Relapsed/Refractory CLL/SLL
January 11th 2023Zanubrutinib demonstrated a superior reduction in the risk of progression or death for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma compared with ibrutinib.